Novel tumor vaccine gp96-Ig fusion heat shock protein in advanced non-small cell lung cancer (NSCLC) patients who have failed palliative chemotherapy and erlotinib

被引：0
|
作者：
Podack, E.
Raez, L. E.
Fisher, E.
Leibovitch, E.
Gomez, J. E.
Baldie, P.
Tolba, K. A.
Santos, E. S.
Walker, G.
机构：
[1] Univ Miami, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami, Sch Med, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Population-based analysis of time to palliative chemotherapy (TPC) and survival in advanced non-small cell lung cancer (NSCLC).
    Noonan, Krista
    Tong, King Mong
    Sun, Sophie
    Melosky, Barbara L.
    Murray, Nevin
    Laskin, Janessa J.
    Ho, Cheryl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Serum levels of Magic Roundabout protein in patients with advanced non-small cell lung cancer (NSCLC)
    Görn, M
    Anige, M
    Burkholder, I
    Müller, B
    Scheffler, A
    Edler, L
    Boeters, I
    Panse, J
    Schuch, G
    Hossfeld, DK
    Laack, E
    LUNG CANCER, 2005, 49 (01) : 71 - 76
  • [43] Weekly Paclitaxel as Third Line Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Belloni, P.
    Cozzi, C.
    Zannier, F.
    Corradini, G.
    Candido, P.
    Della Torre, S.
    Toniolo, D.
    Fariciotti, A.
    Vismara, A.
    Bollina, R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S538 - S538
  • [44] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [45] What is the place of clinical variables in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy?
    Berhoune, M.
    Fabre-Guillevin, E.
    Banu, E.
    Scotte, F.
    Bonan, B.
    Medioni, J.
    Cojocarasu, O.
    Rideller, K.
    Ayllon, J.
    Levy, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?
    Daga, H.
    Takeda, K.
    Kiyota, H.
    Tokunaga, S.
    Nanjo, S.
    Sumitani, M.
    Shoji, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?
    Clark, G
    Cagnoni, R
    Ptaszynski, M
    Hamilton, M
    Santabábara, P
    Christy-Bittel, J
    Geiger, B
    McCarthy, S
    Onetto, N
    LUNG CANCER, 2005, 49 : S368 - S368
  • [48] Erlotinib and bevacizumab in chemotherapy-naive performance status 2 patients with advanced non-small cell lung cancer
    Al Baghdadi, T.
    Hanna, N.
    Bhatia, S.
    McClean, J.
    Johnson, C.
    Yu, M.
    Taber, D.
    Harb, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    Hensing, T. A.
    Fidler, M. J.
    Wong, F.
    Polish, A.
    Watkin, W.
    Basu, S.
    Kaiser-Walters, K. A.
    Pool, M.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
12345